Thiogenesis Therapeutics, Corp. (TSXV:TTI)

Canada flag Canada · Delayed Price · Currency is CAD
0.6500
+0.0200 (3.17%)
At close: Nov 28, 2025
-4.41%
Market Cap33.69M
Revenue (ttm)n/a
Net Income (ttm)-6.82M
Shares Out51.84M
EPS (ttm)-0.14
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume5,000
Average Volume30,297
Open0.6500
Previous Close0.6300
Day's Range0.6500 - 0.6500
52-Week Range0.5100 - 0.8800
Beta0.65
RSI44.18
Earnings DateNov 17, 2025

About Thiogenesis Therapeutics

Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. Its lead product candidate is TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and rett syndrome. The company is headquartered in Toronto, Canada. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Patrice Rioux
Country Canada
Stock Exchange TSX Venture Exchange
Ticker Symbol TTI
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.